Diagnosis and treatment of unilateral forms of primary aldosteronism

Current Hypertension Reviews

Volumn 9, Issue 2, 2013, Pages 156-165

  Viola, Andrea ^a   Tizzani, Davide ^a   Monticone, Silvia ^a   Crudo, Valentina ^a   Galmozzi, Maddalena ^a   Burrello, Jacopo ^a   Versace, Karine ^b   Loiacono, Maria ^a   Veglio, Franco ^a   Mulatero, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b AOU San Giovanni Battista di Torino   (Italy)

Author keywords

Adrenal vein sampling; Aldosterone; Aldosterone producing adenoma; Endocrine hypertension; Familial hyperaldosteronism; Primary aldosteronism

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; CORTICOTROPIN; CREATININE; FUROSEMIDE; HYDROCORTISONE; LOSARTAN;

ADRENAL CORTEX CARCINOMA; ADRENAL HYPERPLASIA; ADRENALECTOMY; BLOOD SAMPLING; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; ESSENTIAL HYPERTENSION; FAMILY HISTORY; HUMAN; HYPERALDOSTERONISM; HYPERCORTISOLISM; HYPERTENSION; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY HYPERALDOSTERONISM; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SLEEP DISORDERED BREATHING;

ADENOMA; ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; ALDOSTERONE; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84881489195     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/15734021113099990008     Document Type: Review

References (99)

1. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-81.
2. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-8.
3. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-5.
4. Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-8.
5. Reincke M, Rump LC, Quinkler M, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009; 94: 869-75.
6. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-9.
7. Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J 2011; 58: 711-21.
8. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-50.
9. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-5.
10. Hannemann A, Wallaschofski H. Prevalence of Primary Aldosteronism in Patient's Cohorts and in Population-based Studies-A Review of the Current Literature. Horm Metab Res 2012; 44: 157-62.
11. Willenberg HS, Spath M, Maser-Gluth C, et al. Sporadic solitary aldosterone-and cortisol-co-secreting adenomas: endocrine, histological and genetic findings in a subtype of primary aldosteronism. Hypertens Res 2010; 33: 467-72.
12. Fallo F, Bertello C, Tizzani D, et al. Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study. J Hypertens 2011; 29: 1773-7.
13. Hiraishi K, Yoshimoto T, Tsuchiya K, et al. Clinicopathological features of primary aldosteronism associated with subclinical Cushing's syndrome. Endocr J 2011; 58: 543-51.
14. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 betahydroxylase/ aldosterone synthase gene causes glucocorticoidremediable aldosteronism and human hypertension. Nature 1992; 355: 262-5.
15. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol 1991; 18: 283-6.
16. Mulatero P, Tizzani D, Viola A, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011; 58: 797-803.
17. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 2008; 93: 3117-23.
18. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-72.
19. Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012; 59: 235-40.
20. Scholl UI, Nelson-Williams C, Yue P, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci USA 2012; 109: 2533-38.
21. Charmandari E, Sertedaki A, Kino T, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and earlyonset autosomal dominant hypertension. J Clin Endocrinol Metab 2012; 97: E1532-39.
22. Mulatero P, Monticone S, Rainey W, Veglio F, Williams TA. Role of KCNJ5 mutations in familial and sporadic primary aldosteronism. Nat Rev Endocrinol In press.
23. Monticone S, Viola A, Tizzani D, et al. Primary Aldosteronism: Who Should be Screened? Horm Metab Res 2011; 44: 163-9.
24. Mulatero P, Monticone S, Bertello C, et al. Confirmatory tests in the diagnosis of primary aldosteronism. Horm Metab Res 2010; 42: 406-10.
25. Mulatero P, Milan A, Fallo F, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2618-23.
26. Mulatero P, Bertello C, Garrone C, et al. Captopril test can give misleading results in patients with suspect primary aldosteronism. Hypertension 2007; 50: e26-7.
27. Westerdahl C, Bergenfelz A, Isaksson A, Valdemarsson S. Captopril suppression: limitations for confirmation of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2011; 12: 326-32.
28. Mulatero P, Curnow KM, Aupetit-Faisant B, et al. Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. J Clin Endocrinol Metab 1998; 83: 3996-4001.
29. Mulatero P, Veglio F, Pilon C, et al. Diagnosis of glucocorticoidremediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998; 83: 2573-5.
30. Giacchetti G, Mulatero P, Mantero F, Veglio F, Boscaro M, Fallo F. Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis. Trends Endocrinol Metab 2008; 19: 104-8.
31. Seccia TM, Miotto D, De Toni R, et al. Chromogranin A measurement for assessing the selectivity of adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab 2011; 96: E825-9.
32. Johnson PT, Horton KM, Fishman EK. Adrenal imaging with multidetector CT: evidence-based protocol optimization and interpretative practice. Radiographics 2009; 29: 1319-31.
33. Patel SM, Lingam RK, Beaconsfield TI, Tran TL, Brown B. Role of radiology in the management of primary aldosteronism. Radiographics 2007; 27: 1145-57.
34. Foti G, Faccioli N, Manfredi R, Mantovani W, Mucelli RP. Evaluation of relative wash-in ratio of adrenal lesions at early biphasic CT. AJR Am J Roentgenol 2010; 194: 1484-91.
35. Terzolo M, Stigliano A, Chiodini I, et al. AME Position Statement on adrenal incidentaloma. Eur J Endocrinol 2011; 164: 851-70.
36. Lingam RK, Sohaib SA, Vlahos I, et al. CT of primary hyperaldosteronism (Conn's syndrome): the value of measuring the adrenal gland. AJR Am J Roentgenol 2003; 181: 843-9.
37. Yamada T, Ishibashi T, Saito H et al, Adrenal adenomas: relationship between histologic lipid-rich cells and CT attenuation number. Eur J Radiol 2003; 48: 198-202.
38. Auchus RJ. Primary aldosteronism and a Texas two-step. Rev Endocr Metab Disord 2011; 12: 37-42.
39. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005; 25 Suppl 1: S143-58.
40. Harvey A, Kline G, Pasieka JL. Adrenal venous sampling in primary hyperaldosteronism: comparison of radiographic with biochemical success and the clinical decision-making with "less than ideal" testing. Surgery 2006; 140: 847-53; discussion 853-5.
41. Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol (Oxf) 2009; 70: 14-7.
42. Vonend O, Ockenfels N, Gao X, et al. Adrenal venous sampling: evaluation of the German Conn's registry. Hypertension 2011; 57: 990-5.
43. Weinberger MH, Grim CE, Hollifield JW et al. Primary aldosteronism: diagnosis, localization, and treatment. Ann Intern Med 1979; 90: 386-95.
44. Seccia TM, Miotto D, De Toni R, et al. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension 2009; 53: 761-6.
45. Monticone S, Satoh F, Giacchetti G, et al. Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. Hypertension 2012; 59: 840-6.
46. Mengozzi G, Rossato D, Bertello C, et al. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. Clin Chem 2007; 53: 1968-71.
47. Auchus RJ, Michaelis C, Wians FH Jr., et al. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism. Ann Surg 2009; 249: 318-21.
48. Reardon MA, Angle JF, Abi-Jaoudeh N, et al. Intraprocedural cortisol levels in the evaluation of proper catheter placement in adrenal venous sampling. J Vasc Interv Radiol 2011; 22: 1575-80.
49. Rossi E, Regolisti G, Perazzoli F, et al. Intraprocedural cortisol measurement increases adrenal vein sampling success rate in primary aldosteronism. Am J Hypertens 2011; 24: 1280-5.
50. Betz MJ, Degenhart C, Fischer E, et al. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. Eur J Endocrinol 2011; 165: 301-6.
51. Mulatero P, Bertello C, Sukor N, et al. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. Hypertension 2010; 55: 667-73.
52. Ceral J, Solar M, Krajina A, Ballon M, Suba P, Cap J. Adrenal venous sampling in primary aldosteronism: a low dilution of adrenal venous blood is crucial for a correct interpretation of the results. Eur J Endocrinol 2010; 162: 101-7.
53. Solar M, Ceral J, Krajina A, et al. Adrenal venous sampling: where is the aldosterone disappearing to? Cardiovasc Intervent Radiol 2010; 33: 760-5.
54. Zelinka T, Maek M, Vlková J, et al. Discrepant results of adrenal venous sampling in seven patients with primary aldosteronism. Kidney Blood Press Res 2012; 35: 205-10.
55. Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003; 21: 2149-57.
56. Auchus RJ, Chandler DW, SingeethamS, et al. Measurement of 18-hydroxycorticosterone during adrenal vein sampling for primary aldosteronism. J Clin Endocrinol Metab 2007; 92: 2648-51.
57. Nakamura Y, Satoh F, Morimoto R, et al. 18-oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism. J Clin Endocrinol Metab 2011; 96: E1272-8.
58. Kempers MJ, Lenders JW, van Outheusden L, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009; 151: 329-37.
59. Doppman JL, Gill JR Jr., Miller DL, et al. Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: reliability of CT. Radiology 1992; 184: 677-82.
60. Mulatero P, Bertello C, Rossato D, et al. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 2008; 93: 1366-71.
61. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136: 1227-35.
62. Nwariaku FE, Miller BS, Auchus R, et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 2006; 141: 497-502; discussion 502-3.
63. Minami I, Yoshimoto T, Hirono Y, Izumiyama H, Doi M, Hirata Y. Diagnostic accuracy of adrenal venous sampling in comparison with other parameters in primary aldosteronism. Endocr J 2008; 55: 839-46.
64. Letavernier E, Peyrard S, Amar L, Zinzindohoue F, Fiquet B, Plouin PF. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 2008; 26: 1816-23.
65. Blumenfeld JD, Sealey JE, Schlussel Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877-85.
66. Irony I, Kater CE, Biglieri EG, Shackleton CH. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990; 3: 576-82.
67. Sonoyama T, Sone M, Miyashita K, et al. Significance of adrenocorticotropin stimulation test in the diagnosis of an aldosterone-producing adenoma. J Clin Endocrinol Metab 2011; 96: 2771-8.
68. Phillips JL, Walther MM, Pezzullo JC, et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000; 85: 4526-33.
69. Mosso L, Gomez-Sanchez CE, Foecking MF, Fardella C. Serum 18-hydroxycortisol in primary aldosteronism, hypertension, and normotensives. Hypertension 2001; 38: 688-91.
70. Mulatero P, di Cella SM, Monticone S, et al. 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab 2012; 97: 881-9.
71. Yen RF, Wu VC, Liu KL, et al. 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med 2009; 50: 1631-7.
72. Burton TJ, Mackenzie IS, Balan K, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab 2011; 97: 100-9.
73. Jacobsen NE, Campbell JB, Hobart MG. Laparoscopic versus open adrenalectomy for surgical adrenal disease. Can J Urol 2003; 10: 1995-9.
74. Walz MK, Gwosdz R, Levin SL, et al. Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia. World J Surg 2008; 32: 847-53.
75. Ishidoya S, Ito A, Sakai K, et al. Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol 2005; 174: 40-3.
76. White ML, Gauger PG, Doherty GM, et al. The role of radiologic studies in the evaluation and management of primary hyperaldosteronism. Surgery 2008; 144: 926-33.
77. Shen WT, Lim RC, Siperstein AE, et al. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg 1999; 134: 628-31; discussion 631-2.
78. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
79. Rossi GP, Bolognesi M, Rizzoni D, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008; 51: 1366-71.
80. Chiou TT, Chiang PH, Fuh M, et al. Factors determining cardiovascular and renal outcomes after adrenalectomy in patients with aldosterone-producing adrenal adenoma. Tohoku J Exp Med 2009; 218: 17-24.
81. Zarnegar R, Young WF Jr., Lee J, et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 2008; 247: 511-8.
82. van der Linden P, Steichen O, Zinzindohoue F, Plouin PF. Blood pressure and medication changes following adrenalectomy for unilateral primary aldosteronism: a follow-up study. J Hypertens 2012; 30: 761-9.
83. Mulatero P, Monticone S, Veglio F. Diagnosis and treatment of primary aldosteronism. Rev Endocr Metab Disord 2011; 12: 3-9.
84. Pagny JY, Chatellier G, Duclos JM, Plouin PF, Corvol P, Menard J. [Results of the surgical treatment of Conn's adenomas]. Arch Mal Coeur Vaiss 1987; 80: 995-8.
85. Weigel RJ, Wells SA, Gunnels C, Leight GS. Surgical treatment of primary aldosteronism. Ann Surg 1994; 219: 347-52.
86. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001; 135: 258-61.
87. Rossi H, Kim A, Prinz RA. Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. Am Surg 2002; 68: 253-56; discussion 256-57.
88. Lumachi F, Ermani M, Basso SM, Armanini D, Iacobone M, Favia G. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg 2005; 71: 864-9.
89. Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg 2005; 29: 155-59.
90. Pang TC, Bambach C, Monaghan JC, et al. Outcomes of laparoscopic adrenalectomy for hyperaldosteronism. ANZ J Surg 2007; 77: 768-73.
91. Mourad JJ, Girerd X, Milliez P, Lopez-Sublet M, Lejeune S, Safar ME. Urinary aldosterone-to-active-renin ratio: a useful tool for predicting resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenomas. Am J Hypertens 2008; 21: 742-7.
92. Kline GA, Harvey A, Jones C, et al. Adrenal vein sampling may not be a gold-standard diagnostic test in primary aldosteronism: final diagnosis depends upon which interpretation rule is used. Int Urol Nephrol 2008; 40: 1035-43.
93. Giacchetti G, Ronconi V, Rilli S, Guerrieri M, Turchi F, Boscaro M. Small tumor size as favorable prognostic factor after adrenalectomy in Conn's adenoma. Eur J Endocrinol 2009; 160: 639-46.
94. Murashima M, Trerotola SO, Fraker DL, Han D, Townsend RR, Cohen DL. Adrenal venous sampling for primary aldosteronism and clinical outcomes after unilateral adrenalectomy: a singlecenter experience. J Clin Hypertens (Greenwich) 2009; 11: 316-23.
95. Wu VC, Chueh SC, Chang HV, et al. Association of kidney function with residual hypertension after treatment of aldosteroneproducing adenoma. Am J Kidney Dis 2009; 54: 665-73.
96. Mathur A, Kemp CD, Dutta U, et al. Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg 2010; 211: 384-90.
97. Wang B, Zhang G, Ouyang J, et al. Association of DNA polymorphisms within the CYP11B2/CYP11B1 locus and postoperative hypertension risk in the patients with aldosteroneproducing adenomas. Urology 2010; 76: 1018 e1-7.
98. Waldmann J, Maurer L, Holler J, et al. Outcome of surgery for primary hyperaldosteronism. World J Surg 2011; 35: 2422-7.
99. Celen O, O'Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 1996; 131: 646-50.